Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Pharmacogenomics ; 23(11): 627-638, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35880554

ABSTRACT

Background: The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: 56 SNPs in five genes (CYP3A4, CYP3A5, ABCB1, TUBB1 and CYP2C8) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. Results:TUBB1-rs151352 (hazard ratio: 0.52) and CYP2C8-rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and CYP2C8-rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis. ABCB1-rs17327624 correlated with severe toxicity ≥grade 3 (odds ratio: 8.56) and CYP2C8-rs11572093 with asthenia (odds ratio: 8.12). Conclusion: Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel. Nonetheless, the small sample size and the high number of SNPs analyzed mean that the results are only hypothesis-generating and require further validation.


Subject(s)
Antineoplastic Agents , Prostatic Neoplasms, Castration-Resistant , Taxoids , Humans , Male , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , ATP Binding Cassette Transporter, Subfamily B/genetics , Cytochrome P-450 CYP2C8/genetics , Cytochrome P-450 CYP3A/genetics , Polymorphism, Single Nucleotide , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/genetics , Prostatic Neoplasms, Castration-Resistant/pathology , Taxoids/adverse effects , Taxoids/therapeutic use , Treatment Outcome , Tubulin/genetics
2.
Biomolecules ; 11(6)2021 06 20.
Article in English | MEDLINE | ID: mdl-34202969

ABSTRACT

Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the "obesity paradox", and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology.


Subject(s)
Adaptive Immunity , Immunotherapy , Leptin/immunology , Neoplasm Proteins/immunology , Neoplasms/immunology , Neoplasms/therapy , Animals , Humans , Obesity/immunology
3.
Clin Genitourin Cancer ; 18(6): 452-460, 2020 12.
Article in English | MEDLINE | ID: mdl-32565133

ABSTRACT

INTRODUCTION: The MAJA study compared vinflunine (VFL) plus best supportive care (BSC) maintenance therapy versus BSC alone in advanced urothelial carcinoma responsive to first-line chemotherapy. The primary end point of progression-free survival was achieved. We present the final overall survival (OS) and long-term follow-up safety analyses. PATIENTS AND METHODS: Patients were enrolled, and a subsequent post hoc analysis was performed on the basis of radiologic response or stabilization to first-line cisplatin/gemcitabine (CG) chemotherapy (4-6 cycles), according to Response Evaluation Criteria in Solid Tumors (RECIST). VFL + BSC versus BSC alone were randomly assigned until disease progression. RESULTS: At final analysis, 58 patients (66.7%) had died while 29 (33.3%) had survived; the BSC arm had higher mortality (VFL + BSC, n = 26, 59.1% vs. BSC, n = 32, 74.4%). Median follow-up of surviving patients was 38.8 months (interquartile range, 23.8-61.6). Median OS was 16.7 months (95% confidence interval, 0-34.5) in VFL and 13.2 months (95% confidence interval, 6-20.4) in the BSC groups (hazard ratio, 0.736; 95% confidence interval, 0.44-1.24, P = .182). Post hoc group division did not affect median OS in either study arm. CONCLUSION: Final analysis supported a benefit of VFL in maintenance therapy in patients with disease control after first-line treatment with CG, with no unexpected long-term adverse effects. The study was insufficiently powered to show a significant OS advantage.


Subject(s)
Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Humans , Survival Analysis , Urinary Bladder Neoplasms/drug therapy , Vinblastine/analogs & derivatives , Vinblastine/therapeutic use
4.
Curr Treat Options Oncol ; 20(12): 91, 2019 12 19.
Article in English | MEDLINE | ID: mdl-31853656

ABSTRACT

OPINION STATEMENT: Cancer-associated pain has traditionally been treated with opioid analgesics, often in escalating doses. Opioid-induced constipation (OIC) is a common problem associated with chronic use of opioid analgesics. Typical treatment strategies to alleviate constipation are based on dietary changes, exercise, and laxatives. However, laxatives have a nonspecific action and do not target underlying mechanisms of OIC. This article will review prevalent, clinical presentation and recommendations for the treatment of OIC. An independent literature search was carried out by the authors. We reviewed the literature for randomized controlled trials that studied the efficacy of laxatives, naloxone, and naloxegol in treating OIC. Newer strategies addressing the causal pathophysiology of OIC are needed for a more effective assessment and management of OIC. Finally, traditional recommended therapies are appraised and compared with the latest pharmacological developments. Future research should address whether naloxegol is more efficacious by its comparison directly with first-line treatments, including laxatives.


Subject(s)
Analgesics, Opioid/adverse effects , Neoplasms/complications , Opioid-Induced Constipation/diagnosis , Opioid-Induced Constipation/therapy , Analgesics, Opioid/therapeutic use , Cancer Pain/etiology , Cancer Pain/therapy , Disease Management , Humans , Opioid-Induced Constipation/etiology , Opioid-Induced Constipation/prevention & control , Pain Management
5.
Rev. esp. cardiol. (Ed. impr.) ; 72(9): 749-759, sept. 2019. tab, graf
Article in Spanish | IBECS | ID: ibc-189134

ABSTRACT

La mejora en la supervivencia de los pacientes con cáncer ha puesto de manifiesto el impacto clínico que la cardiotoxicidad tiene en el pronóstico tanto cardiovascular como onco-hematológico, sobre todo cuando motiva la interrupción de terapias antitumorales altamente eficaces. La fibrilación auricular es una complicación frecuente en pacientes con cáncer activo y su tratamiento supone un gran reto. Estos pacientes tienen mayores riesgos tromboembólico y hemorrágico y, sin embargo, no se dispone de escalas específicas para guiar la atención clínica. El objetivo de este documento promovido por los grupos de Cardio-Onco-Hematología y Trombosis de la Sociedad Española de Cardiología y elaborado de manera conjunta con las diferentes áreas de conocimiento de la Sociedad Española de Cardiología y con expertos de la Sociedad Española de Oncología Médica, la Sociedad Española de Oncología Radioterápica y la Sociedad Española de Hematología y Hemoterapia, es proporcionar un enfoque multidisciplinario y práctico para la prevención y el tratamiento de la fibrilación auricular de pacientes con cáncer activo y basado en el consenso de expertos


Improvements in survival among cancer patients have revealed the clinical impact of cardiotoxicity on both cardiovascular and hematological and oncological outcomes, especially when it leads to the interruption of highly effective antitumor therapies. Atrial fibrillation is a common complication in patients with active cancer and its treatment poses a major challenge. These patients have an increased thromboembolic and hemorrhagic risk but standard stroke prediction scores have not been validated in this population. The aim of this expert consensus-based document is to provide a multidisciplinary and practical approach to the prevention and treatment of atrial fibrillation in patients with active cancer. This is a position paper of the Spanish Cardio-Oncology working group and the Spanish Thrombosis working group, drafted in collaboration with experts from the Spanish Society of Cardiology, the Spanish Society of Medical Oncology, the Spanish Society of Radiation Oncology, and the Spanish Society of Hematology


Subject(s)
Humans , Atrial Fibrillation/drug therapy , Anticoagulants/therapeutic use , Neoplasms/complications , Thromboembolism/prevention & control , Atrial Fibrillation/complications , Antineoplastic Agents/therapeutic use , Consensus , Practice Patterns, Physicians'
6.
Rev Esp Cardiol (Engl Ed) ; 72(9): 749-759, 2019 Sep.
Article in English, Spanish | MEDLINE | ID: mdl-31405794

ABSTRACT

Improvements in survival among cancer patients have revealed the clinical impact of cardiotoxicity on both cardiovascular and hematological and oncological outcomes, especially when it leads to the interruption of highly effective antitumor therapies. Atrial fibrillation is a common complication in patients with active cancer and its treatment poses a major challenge. These patients have an increased thromboembolic and hemorrhagic risk but standard stroke prediction scores have not been validated in this population. The aim of this expert consensus-based document is to provide a multidisciplinary and practical approach to the prevention and treatment of atrial fibrillation in patients with active cancer. This is a position paper of the Spanish Cardio-Oncology working group and the Spanish Thrombosis working group, drafted in collaboration with experts from the Spanish Society of Cardiology, the Spanish Society of Medical Oncology, the Spanish Society of Radiation Oncology, and the Spanish Society of Hematology.


Subject(s)
Atrial Fibrillation/complications , Cardiology , Consensus , Medical Oncology , Neoplasms/complications , Societies, Medical , Thromboembolism/prevention & control , Anticoagulants/therapeutic use , Humans , Risk Factors , Spain , Thromboembolism/etiology
7.
Transl Cancer Res ; 8(1): 59-65, 2019 Feb.
Article in English | MEDLINE | ID: mdl-35116734

ABSTRACT

BACKGROUND: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, in particular. Previous studies have demonstrated that the immunological profile in peripheral blood may be a prognostic and/or predictive biomarker in breast cancer. Thus, higher number of regulatory T cells (Tregs) in blood from patients with breast cancer has been reported in relation to normal donors. In the present study, we planned to evaluate the changes in different cell populations in peripheral blood: neutrophils, monocytes and lymphocytes, as well as lymphocyte subpopulations [natural killer (NK), B lymphocytes, T lymphocytes, both CD4+ and CD8+, and Tregs] from patients with local breast cancer (both Her2+ and Her2-), before, during and after neoadjuvant chemotherapy. METHODS: We have employed flow cytometry for the cell analysis of fresh samples obtained before and whilst the neoadjuvant treatment was accomplished. We have studied 50 successive patients from the Breast Cancer Unit of the Virgen Macarena University Hospital during 2 years. RESULTS: Neoadjuvant chemotherapy induced a significant reduction in B cells, especially in Her2- patients, and a reduction in NK cells. CD4+ T cells decreased, whereas CD8+ cells only decreased in Her2- patients. Tregs were also diminished, especially in Her2+ patients, in response to treatment. Thus, higher CD8/Treg ratio was observed in Her2+ patients. A higher percentage of Her2+ patients (66.6%) achieved complete response than Her2- patients (27.5%). Monocytes and neutrophils were not changed in peripheral blood. CONCLUSIONS: Even though the decrease in B cells and NK cells in response to chemotherapy may be deleterious in the neoadjuvant treatment of breast cancer, the decrease in Tregs and CD4 T cells, but not CD8 T cells, increasing the CD8/Treg ratio, especially in Her2+ patients, may reveal a new tool to monitor the immune response in breast cancer treated with chemotherapy in the neoadjuvant setting.

8.
Med. paliat ; 24(2): 89-95, abr.-jun. 2017. graf, tab
Article in Spanish | IBECS | ID: ibc-161293

ABSTRACT

OBJETIVO: El propósito de este estudio fue investigar el grado de concordancia entre pacientes que sufren dolor irruptivo oncológico y los médicos que los tratan en la percepción del dolor y la calidad de vida (CdV). MÉTODO: Se llevó a cabo un estudio multicéntrico, transversal y observacional. La información sobre el dolor y la CdV se recogió mediante las herramientas Brief Pain Inventory (BPI) y EuroQoL five-dimensional questionnaire (EQ-5D), ambas completadas por los médicos y los pacientes. También se recogieron los datos sociodemográficos y clínicos, incluyendo la puntuación de la capacidad funcional ECOG. Para el análisis de la concordancia en las percepciones de la CdV y el dolor entre médicos y pacientes se calcularon los coeficientes de correlación intraclase y el estadístico κ ponderado. Resultado: Un total de 129 médicos y 472 pacientes participaron en el estudio. Casi todos los doctores (98,4%) tenían experiencia previa en el manejo de pacientes con dolor irruptivo oncológico. Con relación a la intensidad de dolor y al impacto de este en la vida cotidiana, los coeficientes de correlación intraclase (todos por encima de 0,84) indicaron que había un alto grado de acuerdo entre las valoraciones de los médicos y la de los pacientes. Para la CdV, se observó una buena concordancia entre médicos y pacientes, con estadísticos κ desde 0,61 (ítem de ansiedad/depresión) a 0,75 (ítem de actividades de la vida diaria). La declaración del dolor experimentado por los pacientes fue de 8 para la intensidad máxima y de 5 para la intensidad media. CONCLUSIONES: En este estudio de práctica clínica habitual, los médicos participantes eran razonablemente conocedores del nivel de funcionalidad y bienestar de sus pacientes, siendo la percepción del componente psicológico (ansiedad/depresión) de la CdV la menos concordante. Estos hallazgos ayudan a conocer mejor la prevalencia e intensidad del dolor, su interferencia con las actividades de la vida diaria y la CdV en pacientes oncológicos con dolor irruptivo oncológico, un paso esencial para mejorar el manejo del dolor asociado a cáncer


OBJECTIVE: To analyse the agreement on perceptions of pain and quality of life (QoL) between patients with cancer-related breakthrough pain and their treating physicians. METHOD: A multicentre, cross-sectional, observational study was performed. Pain and QoL information was collected using the Brief Pain Inventory and the EuroQoL five-dimensional questionnaire completed by physicians and PATIENTS: Agreement between patient- and physician-perceived QoL and pain scores was evaluated using intraclass correlation coefficients and weighted κ statistics. RESULTS: A total of 129 physicians and 472 patients participated in the study. Almost all doctors (98.4%) had previous experience in managing patients with cancer breakthrough pain. For pain intensity and impact of pain on daily life, intraclass correlation coefficients (all exceeding 0.84) indicated that there was strong agreement between physician and patient assessments. For QoL, good concordance was found between patients and physicians, with weighted κ statistic ranging from 0.61 (anxiety/depression item) to 0.75 (daily activities item). Patient pain reports were 8.0 for the worst pain, and 5.0 for mean pain. CONCLUSIONS: In this setting, physicians were reasonably aware of their patients' level of functioning and well-being, with gaps only in the psychological dimension (anxiety/depression) of QoL. These findings contribute to a better understanding of pain prevalence and intensity, interference of pain with daily activities, and QoL in cancer patients with breakthrough pain, and are an essential step towards improving cancer pain management


Subject(s)
Humans , Breakthrough Pain/complications , Neoplasms/complications , Pain Measurement/statistics & numerical data , Pain Management/methods , Quality of Life , Sickness Impact Profile
9.
Rev. esp. cardiol. (Ed. impr.) ; 70(6): 474-486, jun. 2017. ilus, tab, graf
Article in Spanish | IBECS | ID: ibc-163305

ABSTRACT

Los avances en la detección precoz y el tratamiento del cáncer han reducido de manera significativa la mortalidad de los pacientes. Sin embargo, mejorar el pronóstico no es solo curar el tumor, sino prevenir, diagnosticar y tratar eficazmente las complicaciones derivadas de las terapias onco-hematológicas. La toxicidad cardiovascular es un problema ampliamente reconocido con múltiples esquemas terapéuticos; sin embargo, la evidencia científica en el manejo de las complicaciones cardiovasculares de pacientes onco-hematológicos es escasa, pues sistemáticamente se ha excluido de los ensayos clínicos a estos enfermos y las recomendaciones actuales están basadas en consensos de expertos. Es imprescindible crear equipos multidisciplinarios locales para optimizar los resultados en salud de los supervivientes al cáncer. Una preocupación excesiva por la aparición de toxicidad cardiovascular puede impedir terapias potencialmente curativas, mientras que la subestimación de este riesgo compromete el pronóstico vital a largo plazo. El objetivo de este documento, elaborado en colaboración con la Sociedad Española de Cardiología, la Sociedad Española de Oncología Médica, la Sociedad Española de Oncología Radioterápica y la Sociedad Española de Hematología, es actualizar los conocimientos aplicables a la práctica clínica diaria de la cardio-onco-hematología y promover el desarrollo de equipos multidisciplinarios locales que mejoren la salud cardiovascular de los pacientes con cáncer (AU)


Improvements in early detection and treatment have markedly reduced cancer-related mortality. However survival not only depends on effectively cure cancer, but prevention, diagnosis and treatment of cancer-related complications is also needed. Cardiovascular toxicity is a widespread problem across many classes of therapeutic schemes, however scientific evidence in the management of cardiovascular complications of onco-hematological patients is scarce, as these patients have been systematically excluded from clinical trials and current recommendations are based on expert consensus. Multidisciplinary teams are mandatory to decrease morbidity and mortality from both cardiotoxicity and cancer itself. An excessive concern for the occurrence of cardiovascular toxicity, can avoid potentially curative therapies, while underestimating this risk, increases long-term mortality of cancer survivors. The objective of this consensus document, developed in collaboration of the Spanish Society of Cardiology, the Spanish Society of Medical Oncology, the Spanish Society of Radiation Oncology and the Spanish Society of Hematology, is to update the necessary concepts and expertise on cardio-onco-hematology that enable its application in daily clinical practice and to promote the development of local multidisciplinary teams, to improve the cardiovascular health of patients with cancer (AU)


Subject(s)
Humans , Neoplasms/therapy , Cardiotoxicity/epidemiology , Antineoplastic Agents/adverse effects , Radiotherapy/methods , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Patient Care Team/trends
10.
Rev Esp Cardiol (Engl Ed) ; 70(6): 474-486, 2017 Jun.
Article in English, Spanish | MEDLINE | ID: mdl-28330818

ABSTRACT

Improvements in early detection and treatment have markedly reduced cancer-related mortality. However survival not only depends on effectively cure cancer, but prevention, diagnosis and treatment of cancer-related complications is also needed. Cardiovascular toxicity is a widespread problem across many classes of therapeutic schemes, however scientific evidence in the management of cardiovascular complications of onco-hematological patients is scarce, as these patients have been systematically excluded from clinical trials and current recommendations are based on expert consensus. Multidisciplinary teams are mandatory to decrease morbidity and mortality from both cardiotoxicity and cancer itself. An excessive concern for the occurrence of cardiovascular toxicity, can avoid potentially curative therapies, while underestimating this risk, increases long-term mortality of cancer survivors. The objective of this consensus document, developed in collaboration of the Spanish Society of Cardiology, the Spanish Society of Medical Oncology, the Spanish Society of Radiation Oncology and the Spanish Society of Hematology, is to update the necessary concepts and expertise on cardio-onco-hematology that enable its application in daily clinical practice and to promote the development of local multidisciplinary teams, to improve the cardiovascular health of patients with cancer.


Subject(s)
Cardiology/standards , Cardiovascular Diseases/prevention & control , Consensus , Hematology/standards , Medical Oncology/standards , Neoplasms/prevention & control , Primary Prevention/standards , Humans
11.
Pain Pract ; 17(8): 1075-1088, 2017 11.
Article in English | MEDLINE | ID: mdl-28084045

ABSTRACT

BACKGROUND AND OBJECTIVE: Pain is one of the most common symptoms in patients with cancer. The aim of this review is to summarize the most recent literature regarding tapentadol use in oncology patients and moderate or severe pain. DATABASES AND DATA TREATMENT: We have conducted a review of the literature using PubMed, The Cochrane Library, EMBASE, and Google Scholar for all manuscripts published between 2008 and 2016, using the key words "tapentadol," "cancer," "pain," "tumor," and "malignant." RESULTS: Nine studies met the inclusion criteria (four randomized clinical trials and five prospective cohort studies). The scope of the literature was diverse, with 15 instruments used to measure different aspects of pain (intensity, health status, quality of life, psychometric and well-being, perception of change, and neuropathic pain). All these studies concluded that tapentadol is seemingly a well-tolerated and efficacious agent for moderate-severe cancer pain, with few typically mild adverse reactions. However, the most significant detected weaknesses of research were that (1) existing studies do not clearly show a superiority of tapentadol with respect to previous generation opioids, (2) low-to-moderate sample sizes prevent obtaining robust conclusions about effectiveness, (3) there was an absence of noninferiority trials comparing tapentadol vs. fentanyl or oxycodone-naloxone, and (4) there was scarce generalizability of prospective observational studies. CONCLUSION: Tapentadol is seemingly an effective, well-tolerated alternative for moderate or severe cancer pain. Most prospective cohort studies have relatively small samples, are restricted to few research centers, and lack detailed subgroup information. More experience is required to draw valid generalizable conclusions.


Subject(s)
Analgesics, Opioid/therapeutic use , Cancer Pain/drug therapy , Pain Management/methods , Phenols/therapeutic use , Female , Humans , Quality of Life , Tapentadol
12.
J Clin Oncol ; 33(5): 465-71, 2015 Feb 10.
Article in English | MEDLINE | ID: mdl-25559804

ABSTRACT

PURPOSE: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections. PATIENTS AND METHODS: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per µL (1 point), and stress-induced hyperglycemia (2 points). We integrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE. RESULTS: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC). CONCLUSION: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes.


Subject(s)
Antineoplastic Agents/adverse effects , Febrile Neutropenia/chemically induced , Febrile Neutropenia/diagnosis , Adult , Aged , Antineoplastic Agents/administration & dosage , Area Under Curve , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , ROC Curve , Risk Assessment , Risk Factors
13.
Pathol Oncol Res ; 17(3): 455-61, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21279555

ABSTRACT

Recurrent or metastatic GISTs are currently treated with kinase inhibitors since they achieves disease control in 70-85% of patients but this response depend on KIT and PDGFRA gene mutation status. We review the morfological and molecular findings associated to kinase inhibitors administration in GISTs based on the literature on Medline and authors' own experience. The initial response to kinase inhibitors (imatinib mesylate, Gleevec, Novartis) usually is partial and depend on the mutational KIT or PDGFRA state. Amongst patients wih KIT mutations, the best results are achived in those harboring exon 11 (85%) and exon 9 (45%) mutations. GISTs harboring PDGFRA gene mutations generally respond favorably except those involving the Asp842Val mutation. In the absence of KIT/PDGFRA gene mutations, partial response or disease stabilization is reported in 23% and 50% of patients, respectively, and disease progression in 19%. Histological examination of tumors displaying an initial response to imatinib reveals a highly-variable reduction in the number of tumor cells, a decline in the proliferative index, myxohyaline or sclerohyaline stroma, and a varying degree of bleeding and edema, necrosis and cystification. 72% of patients with initial good response to imatinib, display metastases or new nodule growth within an existing clinically-quiescent tumor after 12-36 months of treatment. This secondary resistance is characterized by a number of well-defined morphological and molecular changes. Histologically, the new growths display increased mitotic activity, pleomorphism, an epithelioid or mixed phenotype and persistent KIT expression although more rarely, dedifferentiation and loss of KIT expression (Fig. 4), as well as trans-differentiation into a rhabdomyosarcoma or epithelial phenotype has been reported. Molecularly, 46-67% of patients present additional KIT mutations, generally in the kinase domain (exons 13, 14 and 17) but also in the ATP-binding domain (exons 15,16) of the same allele. Secondary PDGFRA mutations are very rare. Secondary mutations have not been observed in GISTs not harboring KIT/PDGFRA mutations, or in tumors displaying an unusual morphology or loss of CD117 expression. A number of studies highlight the presence of different resistance mutations within different new tumor nodules, as well as the simultaneous development of distinct resistant tumor subclones within a single lesion (acquired polyclonal resistance). Secondary mutation in genes other than KIT/PDGFRA has only been reported in BRAF (Val600Glu).


Subject(s)
Gastrointestinal Stromal Tumors/metabolism , Gastrointestinal Stromal Tumors/pathology , Protein Kinase Inhibitors/therapeutic use , Protein Kinases/chemistry , Protein Kinases/metabolism , Animals , Gastrointestinal Stromal Tumors/drug therapy , Humans , Immunoenzyme Techniques
14.
Pathol Oncol Res ; 13(3): 203-8, 2007.
Article in English | MEDLINE | ID: mdl-17922049

ABSTRACT

We investigated the expression of P-glycoprotein (P-GP) and metallothionein (MT) in a series of 92 GIST and 14 gastrointestinal leiomyosarcomas (GILMS) with the purpose to expand our knowledge on the biological bases of GIST chemo-resistance and to ascertain their significance in patients' prognosis. P-GP expression was more frequent in GIST than in GI-LMS (83.7% vs. 21.4%, p<0.001), with no difference between low- and high-risk GIST (p=1.000) or low- and high-grade GI-LMS (p=0.538). P-GP expression was unrelated to anatomic location (gastric vs. intestinal) in GIST (39/45 vs. 35/43, p=0.770) and in GI-LMS (0/2 vs. 2/6, p=1.000). MT expression was non-significantly higher in GI-LMS than in GIST (35.7% vs. 14.1%, p=0.060), with no difference between low- and high-risk GIST (p=1.000) or low- and high-grade GI-LMS (p=1.000). MT expression was unrelated to the anatomic location (gastric vs. intestinal) in GIST (7/45 vs. 6/43) and GI-LMS (0/2 vs. 1/6) (p=1.000 and p=0.1000, respectively). Overall tumor-specific survival (p< 0.001) and disease-free survival (p<0.001) were different in GIST as compared with GI-LMS, and the number of events was higher in GI-LMS. When the survival analysis took into consideration P-GP or MT expression, the overall survival in GIST was influenced by the expression of MT (p=0.021) but not by that of P-GP (p=0.638). However, in GI-LMS, P-GP expression influenced disease-free survival (p=0.050); in addition, it is important to recognize the limited value of these results because of the low number of cases involved in the study. Differential expression of P-GP and MT might explain the known variability in response to systemic chemotherapy in these tumors. Detection of P-GP and MT seems to add certain prognostic value in GIST (MT) or GI-LMS (P-GP).


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Gastrointestinal Neoplasms/metabolism , Gastrointestinal Stromal Tumors/metabolism , Leiomyosarcoma/metabolism , Metallothionein/metabolism , Aged , Antineoplastic Agents/therapeutic use , Drug Resistance, Neoplasm , Female , Gastrointestinal Neoplasms/diagnosis , Gastrointestinal Neoplasms/drug therapy , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/drug therapy , Gene Expression Regulation, Neoplastic , Humans , Leiomyosarcoma/diagnosis , Leiomyosarcoma/drug therapy , Male , Middle Aged , Prognosis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...